In Stock
Retatrutide is an investigational once-weekly triple-hormone receptor agonist (targeting GIP, GLP-1, and glucagon receptors) developed by Eli Lilly, showing unprecedented weight loss results in trials, with up to ~24% body weight reduction in 48 weeks. Currently in Phase 3 trials (TRIUMPH program), it is designed for obesity, type 2 diabetes, and related conditions, with potential FDA approval expected around summer 2026
PLEASE CONTACT WITH ANY QUESTIONS
GLP-3 RT Reta is an investigational triple receptor agonist This compound is supplied exclusively for research purposes. Research Use Only.
Office Hours: Mon–Sat, 9:00 AM–5:00 PM (By Appointment)
Online Services: Available 24/7
13791 E Rice Place #205 Aurora, CO 80015
Reviews
There are no reviews yet.